Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

NCT05201612 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Grupo Espanol Multidisciplinario del Cancer Digestivo

Collaborators